Mineralys Therapeutics, Inc.
MLYS
$39.20
$0.050.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.82% | -59.41% | -107.62% | -147.31% | -170.85% |
| Total Depreciation and Amortization | 117.86% | 235.29% | 525.00% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,240.00% | 655.75% | 340.36% | 206.98% | 65.78% |
| Change in Net Operating Assets | -140.53% | -138.56% | -271.67% | 227.47% | 672.78% |
| Cash from Operations | -33.41% | -98.04% | -120.09% | -104.89% | -105.93% |
| Capital Expenditure | 100.00% | 37.29% | 37.29% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -966.36% | 152.56% | 202.57% | 171.70% | 122.85% |
| Cash from Investing | -969.93% | 152.43% | 202.44% | 171.64% | 122.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 324.43% | 70.88% | 62.71% | -42.81% | -42.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 65.72% | 58.21% | -506.35% | -- | 63.67% |
| Cash from Financing | 325.73% | 71.26% | 63.28% | -42.86% | -42.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 996.44% | 201.95% | 255.95% | 268.73% | -70.61% |